These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21920801)

  • 1. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.
    Mehra R; Serebriiskii IG; Dunbrack RL; Robinson MK; Burtness B; Golemis EA
    Drug Resist Updat; 2011 Dec; 14(6):260-79. PubMed ID: 21920801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
    Zaryouh H; De Pauw I; Baysal H; Peeters M; Vermorken JB; Lardon F; Wouters A
    Med Res Rev; 2022 Jan; 42(1):112-155. PubMed ID: 33928670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
    Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers.
    Box C; Zimmermann M; Eccles S
    Front Biosci (Landmark Ed); 2013 Jan; 18(2):520-42. PubMed ID: 23276940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.
    Hoellein A; Pickhard A; von Keitz F; Schoeffmann S; Piontek G; Rudelius M; Baumgart A; Wagenpfeil S; Peschel C; Dechow T; Bier H; Keller U
    Oncotarget; 2011 Aug; 2(8):599-609. PubMed ID: 21865609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex.
    Vermeer PD; Colbert PL; Wieking BG; Vermeer DW; Lee JH
    Cancer Res; 2013 Sep; 73(18):5787-97. PubMed ID: 23811940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
    Iberri DJ; Colevas AD
    Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
    Song Q; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
    Reuter CW; Morgan MA; Eckardt A
    Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.
    Egloff AM; Grandis JR
    Semin Oncol; 2008 Jun; 35(3):286-97. PubMed ID: 18544443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
    Price KA; Cohen EE
    Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.
    Ugurluer G; Ozsahin M
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1637-54. PubMed ID: 25134724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.